No abstract

With a cure rate of 95% in patients with HCV infection and ESRD Highlights Sofosbuvir/velpatasvir (SOF/VEL) is approved for patients with HCV infection. There is no dosing recommendation for SOF-based regimens for HCV-infected patients on dialysis. We evaluated SOF/VEL for 12 weeks in HCV-infected patients with end-stage renal disease on dialysis. SOF/VEL was safe and well tolerated, with a cure rate of 95% in our study.

No abstract

Curcumin improved survival and minimized oxidative stress, hepatocellular injury and hepatic necroinflammation, NFkappaB binding and iNOS expression in a rat model of FHF. These findings support the role of ROS, NFkappaB and iNOS in mediating liver insult due to TAA, and that of curcumin as a hepato-protectant.